Endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction.
The global infertility drugs and devices market is estimated to account for US$ 9,702.4 Mn in terms of value by the end of 2019.
Global Infertility Drugs and Devices Market: Drivers
Increasing prevalence of erectile dysfunction is expected to propel growth of the global infertility drugs and devices market over the forecast period. For instance, according to the study ‘The Global Prevalence of Erectile Dysfunction: A Review’, published in BJUI International, in July 2019, the global prevalence of erectile dysfunction was 3–76.5%.
Global Infertility Drugs and Devices Market: Opportunities
R&D in diagnosis of infertility is expected to offer lucrative growth opportunities for players in the global infertility drugs and devices market. For instance, in May 2018, DiaSorin S.p.A launched LIAISON test for the measurement of sex hormone-binding globulin in human serum and plasma for the diagnosis of infertility, decreased libido and erectile dysfunction in men and polycystic ovarian syndrome in women.
Global Infertility Drugs and Devices Market: Restraints
Narrowing of insurance coverage for erectile dysfunction treatment is expected to limit growth of the market. A person with a documented medical condition responsible for the cause of erectile dysfunction may incur insurance benefits. However, sex therapies and medications that have not been approved by the FDA have not been covered under insurance.
The global infertility drugs and devices market was valued at US$ 6,096.7 Mn in 2019 and is forecast to reach a value of US$ 9,702.4 Mn by 2027 at a CAGR of 5.8% between 2020 and 2027. Increasing prevalence of erectile dysfunction is expected to propel growth of the global infertility drugs and devices market over the forecast period.
Infertility Drugs segment held dominant position in the global infertility drugs and devices market in 2019, accounting for 77.0% share in terms of value, increasing prevalence of erectile dysfunction is expected to assist the segment growth
Decreasing birth rate is expected to propel growth of the global infertility drugs and devices market. For instance, according to National Vital Statistics System, the provisional number of births for the U.S. in 2018 was 3,788,235, registering a decrease of 2% from 2017 and the lowest number of births in 32 years.
The adoption of Machine Learning and Artificial Intelligence (AI) in diagnosis of infertility is on the rise. For instance, in May 2020, researchers from Peking University, China, proposed a specialized convolutional neural network architecture to accurately classify human sperm heads based on sperm images.
Global Infertility Drugs and Devices Market: Competitive Landscape
Major players operating in the global infertility drugs and devices market include, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc. Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd.
Global Infertility Drugs and Devices Market: Key Developments
May 2020: Ferring Pharmaceuticals announced that MEGASET-HR, a trial comparing Menopur (menotropins for injection indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program) to recombinant follicle stimulating hormone met its primary endpoint, with Menopur-treated patients experiencing a 35.5% OPR per cycle start after fresh transfer.
May 2020: Aspargo Laboratories, Inc. announced the results of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food & Drug Administration, where the FDA addressed Aspargo's questions and provided guidance on the company’s Sildenafil Oral Spray for the treatment of erectile dysfunction
Scope of the report